Analysts Have Conflicting Sentiments on These NA Companies: Fiserv (FISV), SpyGlass Pharma (Nasdaq: SGP) and Evommune, Inc. (EVMN)
at www.tipranks.com (Mon, 5-Oct 7:01 AM)
Evommune spotlights Phase 2a atopic dermatitis data: EVO301 hit 55% EASI reduction at Week 12 after just two doses
Market Chameleon (Thu, 1-Oct 8:20 AM)
